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ABSTRACT 
Background: the shortage of donors of hepatocyte trans-
plantation therapy led to the use of so-called marginal 
donors. Some donors may have a hepatic illnesses that is 
associated with hepatic preneoplasia with foci of altered 
hepatocytes (FAH).
Aims: to determine whether recipients developed FAH upon 
transplantation with hepatocytes from a preneoplastic liv-
er and whether FAH progresses to a preneoplastic hepato-
cyte-derived tumor (PHDT), up to 60 days after transplantation.
Material and methods: male Wistar adult rats were used as 
donors and recipients. Donors underwent a 2-phase model 
of liver preneoplasia for hepatocyte isolation. Recipients 
underwent a partial two thirds hepatectomy and received 
150,000 hepatocytes. Recipients were euthanized seven and 
60 days after transplantation. The number of FAH per liver 
area, percentage of liver occupied by FAH, the hepatic enzy-
matic profile, the percentage of prothrombin time (PT), the 
proliferative index (PI) and liver morphology were analyzed.
Results: recipients developed few and very isolated FAH. No 
statistical differences were found between hepatic enzyme 
activities and PT. There were no differences between the 
groups with regard to the number of FAH per liver area and 
percentage of liver occupied by FAH after 60 days. The PI 
decreased on day 60 compared to day seven. No morpho-
logical alterations were found.
Conclusions: recipients developed few FAH that did not 
increase in number or size, nor did they progress to PHDT 
and had normal plasma biochemical features and liver mor-
phology up to 60 days post-transplant. Additional studies are 
needed to determine whether FAH development constitutes 
a risk for recipients while waiting for whole organ transplant.
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INTRODUCTION
Hepatocyte transplantation (HT) therapy is the best alterna-
tive therapeutic approach for whole-organ transplantation 
(1,2). An adequate number of human differentiated hepato-
cytes are transplanted into a liver with acute hepatic failure. 
Thus, the liver can survive and restore the normal hepatic 
function based on the liver regeneration capability. Now-
adays, this procedure is in the experimental phase. It has 
also been used as a temporary bridge until the whole-or-
gan transplantation can be performed in patients with liv-
er-based inborn errors in metabolism and acute or chronic 
liver failure (3). 
Nowadays, the number of patients suitable for liver trans-
plantation is progressively increasing. This has given rise 
to a growing imbalance in the number of candidates on 
the waiting list and the number of donors (4). This situation 
has prompted scientists to search for alternative approach-
es in order to increase the number of liver grafts. These 
include the use of “marginal” or “extended donors” for 
whole-organ transplantation or to obtain isolated hepato-
cytes for HT. Although the definition of an extended donor 
has not been thoroughly established, most agree that it 
conveys a higher risk of either physiologic dysfunction or 
infectious/metabolic disease transmission. Extended crite-
ria can be separated into two groups: donor-related risk 
factors and surgical technique-related issues. Donor-related 
risk includes donation after cardiac death, advanced age, 
increased cold ischemia time, ABO incompatibility, steato-
sis, previous malignancies in the donor, hepatitis C virus or 
hepatitis B virus infection, human T-cell lymphotropic virus 
type I/II infection or other active infections. These extend-
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ed criteria donors can generally be accepted or declined 
by the transplant team during evaluation of the allograft 
(5). Some diseases of marginal donors may be associated 
with undetectable subclinical hepatic preneoplasia such as 
patients with non-alcoholic fatty liver disease and non-al-
coholic steatohepatitis, which could progress to a preneo-
plastic hepatocyte-derived tumor (PHDT) in the absence of 
cirrhosis (6).
Since hepatic preneoplasia is an early, clinically undetect-
able stage of the HCC, it is necessary to study the risks 
associated with the transplantation into healthy recipients 
of hepatocytes isolated from livers that could have a sub-
clinical neoplasia. These are characterized by the presence 
of foci of altered hepatocytes (FAH), without cirrhosis. For 
this purpose, a rat model was used and donor livers were 
induced to develop hepatic preneoplasia in order to mim-
ic a potential transplant with a pool of hepatocytes that 
may contain some preneoplastic hepatocytes. The specific 
marker to determine the presence of FAH in rats was used 
in order to perform these experiments. We hypothesized 
that recipient rats transplanted with hepatocytes obtained 
from a preneoplastic liver could develop FAH, which may 
constitute a potential risk for patients.
The present study determined whether recipient rats devel-
oped FAH upon transplantation with hepatocytes from a 
preneoplastic rat liver. The number of FAH growth and per-
centage of liver occupied by foci, the proliferative index and 
the potential progression of FAH into PHDT up to 60 days 
after transplantation were evaluated.
MATERIAL AND METHODS 
Animals
Two male adult Wistar rats (300-350 g body weight) were 
maintained per cage on a constant 12 hour light/dark cycle 
under controlled temperature and humidity conditions. 
They had free access to tap water and were fed with stan-
dard rat pellets ad libitum. All the experimental protocols 
were performed according to the NIH “Guide for the Care 
and Use of Laboratory Animals” (7) and approved by the 
“Guide for the Care and Use of Laboratory Animals Com-
mittee”, Biochemical and Pharmaceutical Faculty, UNR, Res-
olution No. 6109/012. All surgeries were performed under a 
ketamine-xilazine anesthetic combination (70 mg/kg body 
weight and 2.1 mg/kg body weight, intraperitoneal, respec-
tively).
Reagents
Diethilnitrosamine (DEN), 2-actylaminofluorene (2-AAF) 
and collagenase type IV of Clostridium histolyticum were 
obtained from Sigma Chemical Co. (St Louis, MO). Rabbit 
polyclonal anti-GST3/GST-p antibody was purchased from 
Abcam® (AB106268, Boston, USA). The anti-proliferating 
cell nuclear antigen (PCNA) antibody was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). The bioti-
nylated goat anti-rabbit secondary antibody and horserad-
ish-peroxidase-conjugated streptavidin (HRP CytoScan 
Detection Kit) were obtained from Cell Marque (CMD302, 
USA). The DAB Substrate Kit was purchased from Cell 
Marque (957D-20, USA). Reagents for enzymatic deter-
minations were provided by Wiener Laboratories S.A.I.C. 
(Rosario, Argentina).
Pre-neoplasia induction in donors (group D)
Animals of group D (n = 3) were subjected to a 2-phase 
model (initiation-promotion) of chemical hepatocarcinogen-
esis to induce hepatic pre-neoplasia based on the Solt-Far-
ber method (8) and adapted by Álvarez et al. (9). This model 
mimics the early events of the latent period of clinically 
undetectable human carcinogenesis (10). The initiation 
stage was performed by the administration of two intra-
peritoneal necrogenic doses of the initiator agent DEN (150 
mg/kg body weight), two weeks apart. Administration of 
the promoter drug 2-AAF (11,12) was performed one week 
after the last injection of DEN. The 2-AAF was dissolved in 
dimethyl sulfoxide and then suspended in corn oil to a final 
concentration of 8 mg/ml. Rats received 20 mg/kg body 
weight of 2-AAF by gavage for four consecutive days per 
week for three weeks. After six weeks of treatment, the liv-
ers from group D developed FAH (9). Animals that received 
the vehicles of the drugs instead of DEN+2-AAF were used 
as the vehicle controls (n = 3). 
Hepatocyte isolation 
Hepatocytes from group D were isolated by liver collage-
nase perfusion followed by mechanical disruption, as previ-
ously described by Seglen (13). Briefly, a laparoscopic exci-
sion was performed in the abdominal cavity after rats were 
anesthetized and a 14 G catheter was introduced into portal 
vein. An open perfusion (non-recirculating) of the liver was 
started for two minutes, with calcium-free Ringer solution 
(NaCl 137 mM; NaHCO3 26 mM; Na2HPO4 0.6 mM; KCl 5.4 
mM; glucose 5.6 mM) supplemented with HEPES (3 g/l) and 
EGTA (0.24 g/l), to deplete endogenous calcium (14). For tis-
sue digestion, the liver was perfused in a non-recirculating 
system with the same Ringer solution without EGTA, with 
the addition of MgSO4 (1 mM), collagenase type IV (specific 
activity: 249 U/mg, perfused for nine minutes with a final 
concentration in the perfusion media of 4,300 U/l) and CaCl2 
(2.5 mM). The liver was removed and submerged in the 
solution with collagenase and disrupted mechanically. The 
isolated hepatocytes were subsequently filtered through 
a 40 µm-nylon membrane. Non-parenchymatic and other 
cells were separated by a low-speed centrifugation (30 g, 
two minutes) and the pellet was washed three times with 
media without collagenase. Perfusion solutions were bub-
bled with oxygen for 15 minutes at pH = 7.40-7.50, with an 
osmolarity of 295-305 mOsm. Cell viability was evaluated 
via trypan blue exclusion (15).
Partial hepatectomy of recipients
Recipients (group R) underwent a two-thirds hepatectomy 
by the removal of the central and the right lateral lobes, as 
originally described by Higgins and Anderson (16). Partial 
hepatectomy is used in many models of HT as an exogenous 
factor to enhance hepatocyte division in the recipient liver 
(17). All the surgeries were performed between 10 a.m. and 
2 p.m. in order to avoid alterations due to circadian rhythm.
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Group R received 1.5 x 105 hepatocytes in 200 µl of Ringer 
solution. Hepatocyte solutions were injected directly into 
the splenic pulp using a tuberculin syringe with a G21 (0.8 x 
25 mm) needle (18) immediately after partial hepatectomy; 
1.5 x 105 hepatocytes were used, based on bibliographic 
references (19) to ensure that a portal thrombosis did not 
occur. In addition, a simulation of the transplant was per-
formed by injecting the animals (n = 6) with only the vehicle 
used in the hepatocyte solution (group Sham). Six recip-
ients were used for each rat from group D. Animals from 
group R and the Sham group were euthanized seven and 60 
days after transplantation (n = 3 for each time) and the livers 
were removed and processed. These times were chosen as 
the liver is still in the regeneration process at day 7 (20) and 
day 60 in order to determine whether FAH developed in 
recipient livers augmented or progressed to a PHDT.
Post-transplant studies
Histological analysis
Pieces of all hepatic lobules were fixed in 10% v/v formal-
dehyde and paraffin embedded for histological studies. To 
analyze liver morphology and fibrosis, 4 µm sections were 




To investigate the presence of FAH, sections of all samples 
obtained were mounted and immunohistochemical detec-
tion was performed using an antibody against the placental 
form of rat glutathione S-transferase (rGST-Pi). This isozyme 
has been described as the best effective marker of hepatic 
preneoplasia in rats (21). Briefly, deparaffinized tissue sec-
tions were treated with 3% H2O2 in methanol for ten minutes 
to remove endogenous peroxidase and were then micro-
waved in 10 mM buffer citrate solution for ten minutes at 
96 °C for antigen retrieval. Normal serum was applied to 
the slides to block nonspecific binding and the slides were 
subsequently incubated with a rabbit polyclonal antibody 
against rGST-Pi, diluted 1/250, at 4 °C overnight. The slides 
were incubated with biotinylated goat anti-rabbit secondary 
antibody and then with horseradish-peroxidase-conjugat-
ed-streptavidin. Signals were detected with the DAB sub-
strate kit, followed by hematoxylin counterstaining. 
After immunohistochemistry, the number of FAH per cm2 
of hepatic tissue and the percentage of liver occupied by 
FAH were calculated. To determinate the first parameter, the 
area occupied by the hepatic tissue was calculated using a 
NIH imaging analysis system (ImageJ, U. S. National Insti-
tutes of Health, Bethesda, Maryland, USA) and the num-
ber of FAH was counted in the entire casted tissue using 
light field microscopy. To determinate the percentage of 
liver occupied by foci according to the modified Saltykov’s 
method (22), a representative number of field sections (usu-
ally 1-1.5 cm2 of tissue per animal) from recipient tissue 
samples were collected using a digital camera (Olympus 
D-360, Tokyo, Japan) attached to a light field microscope 
(Olympus, U-MDOB model). The images were processed 
using the corresponding analysis software (ImageJ, U. S. 
National Institutes of Health, Bethesda, Maryland, USA). 
The detection of rGST-Pi positive FAH was also performed 
in group D (lobe removed prior to hepatocyte isolation) and 
in the negative control group. FAH quantification was not 
performed in group D. 
Determination of proliferative index
To investigate differences in the proliferation activity among 
the experimental groups, liver slices were examined by 
immunohistochemical staining with anti-proliferating cell 
nuclear antigen (PCNA, 1/3200) antibody, according to the 
method of Greenwell et al. (23). Proliferative index (PI) was 
expressed as the number of proliferating cells (in G1, S, 
G2, and M phases) per 100 hepatocytes, in ten high-power 
fields (9).
Enzymatic activities and percentage of prothrombin time 
determinations
Blood samples were obtained via cardiac puncture under 
anesthesia at seven and 60 days post-transplantation to 
determinate alkaline phosphatase (ALP) and alanine and 
aspartate aminotransferases (alanine aminotransferase 
[ALT] and aspartate aminotransferase [AST], respective-
ly) activities. The percentage of prothrombin time (PT) 
was determined using spectrophotometry at 25 °C using 
fresh serum. For PT measurement, 2.5 ml blood was drawn 
into a test tube containing 0.25 ml of sodium citrate and 
expressed as a unit known as the Quick value. In this case, 
the measured PT was expressed in relation to the coagu-
lation time of a healthy individual. The value obtained was 
the “percentage of the standard value” (24,25). 
Statistical analysis 
Results were expressed as the mean ± SEM. The number 
of FAH per cm2 of hepatic tissue and the percentage of 
liver occupied by foci were analyzed using the indepen-
dent sample t-tests. The results of PI were evaluated by 
two-way analysis of variance (ANOVA). The comparison 
of means was performed using the Tukey’s test. ALP, AST 
and ALT activities and PT data were analyzed by two-way 
parametric or non-parametric ANOVA, as appropriate. An 
aligned-rank transformation of the data was used when the 
assumptions of normality and homoscedasticity (which are 
requirements for a classical analysis) were not met. Data 
were analyzed using the ARTool packages and lsmeans of 




Liver architecture was conserved in the Sham and R groups. 
Endothelial cells were attached to the perisinusoidal extra-
cellular matrix, hepatocyte cords were preserved and sinu-
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soids and Kupffer cells appeared normal at seven and 60 
days post- transplantation (Fig. 1).
Immunohistochemical studies
All rats from group D had abundant FAH in the liver paren-
chyma at the end of the treatment to induce hepatic preneo-
plasia. As expected, animals that received only vehicles of 
the drugs did not have FAH. There were no signs of cirrhosis 
in group D (Fig. 2). Whereas, all animals in group R had very 
few, small and scattered FAH, as expected. The sham rats 
did not develop any FAH (Fig. 3A).
FAH quantification 
The number of FAH per cm2 of hepatic tissue and the per-
centage of liver occupied by foci were analyzed. The number 
of FAH reflects the amount of initiated cells capable of devel-
oping into clones of FAH, whereas the volume percentage 
generally reflected the growth rate and total cellular popu-
lation of the FAH (26). There were no statistical differences 
between the number and percentage volume occupied by 
Fig. 1. Histological analysis. The sinusoidal and 
hepatocyte architectures (H&E staining) were conserved. 
No morphological alterations were seen upon 
transplantation in the Sham and R groups at both times 
of euthanasia. Portal areas (PA) and central vein (CV). 
Magnification: 200X.
Fig. 3. Immunohistochemical studies of rGSTPi expression 
and FAH quantification performed in group R. A. Very few 
and scattered FAH were found in group R at seven (R7d) 
and 60 (R60d) days after transplantation (asterisks, right 
panel). The Sham group did not develop FAH, either seven 
days (Sham7d) or 60 days (Sham60d) post-transplant (left 
panel). Magnification: 100X. B. Number of FAH/cm2 of 
liver tissue and the percentage of liver as FAH. Each bar 
represents the mean ± SEM. No statistically significant 
differences were found between these parameters at seven 
and 60 days post-transplantation.
Fig. 2. Immunohistochemical and fibrosis studies performed in livers of group D animals before hepatocyte isolation 
and vehicle controls. D: (+) GSTPi: abundant FAH (asterisks) were present in the hepatic parenchyma of group D at 
the end of preneoplastic induction. Vehicle controls: representative area of the hepatic parenchyma from animals that 
received the vehicles of the drugs. No FAH developed. D: (-) fibrosis: direct red 80 stain showed normal red collagen 
fibers deposition (arrows) in group D livers. CV: central vein; PA: portal area. Magnification: 100X.
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FAH at seven and 60 days post-transplantation. The number 
of FAH in group R at seven days was 1.76 ± 0.45 and 1.75 ± 
0.26 at 60 days. The volume percentages of FAH in group R at 
seven days was 2.63 x 10-3 ± 1.84 x 10-4 and 2.55 x 10-3 ± 4.80 
x 10-4 at 60 days. These results are summarized in figure 3B. 
Determination of PI
PI values are summarized in table 1. Figure 4 shows repre-
sentative images of PCNA staining, with a marked decrease 
in the number of positive hepatocytes after 60 days with 
respect to seven days in both groups. Furthermore, immu-
nohistochemistry showed an increment in PI in group R 
with respect to the Sham group at seven days.
Enzymes activities and PT determination 
ALT activity of group R was significantly higher than the 
Sham group seven days after transplantation and was 
comparable to the value after 60 days. ALT in the Sham 
group after seven days was 17.2 (UI/l) ± 1.4 and 17.1 (UI/l) 
± 1.8 after 60 days, and 28.9 ± 3.0 in group R after seven 
days and 16.8 ± 2.1 in group R after 60 days. There were 
no statistically significant differences between the groups 
60 days after transplant (Fig. 5A). There were no statisti-
cally significant differences between AST, ALP and PT in 
the Sham group at seven and 60 days post-transplant. AST 
(UI/l) was 47 ± 8.9 after seven days and 53.3 ± 4.4 after 60 
days in the Sham group and 70.3 ± 8.1 after seven days 
and 54.3 ± 2.9 after 60 days in group R. ALP (UI/l) was 280.3 
± 16.3 after seven days and 285.7 ± 8.9 after 60 days in the 
Sham group and 384.0 ± 40.5 after seven days and 269.0 ± 
14.6 after 60 days in group R. PT (%) was 114.0 ± 3.9 after 
seven days and 111.7 ± 1.7 after 60 days in the Sham group 
and 105.2 ± 3.3 after seven days and 104.3 ± 2.5 after 60 
days in group R (Figs. 5B-D). 
Fig. 4. PCNA immunohistochemistry of rat liver from 
group R. Representative images showing positive PCNA 
cells (arrows) seven days (R7D) and 60 days (R60D) post-
transplantation. Magnification 200X.
Fig. 5. Hepatic enzymatic activities and percentage of prothrombin time. Each bar represents the mean ± SEM. A. ALT 
activity. *p < 0.05 vs Sham at day 7. #p < 0.05 vs Group R at day 60. B. AST activity. C. ALP activity. D. Percentage of 
prothrombin time. 
Table 1. PCNA proliferative index (PI)
Days Group PI
7 SHAM 13.8 ± 0.27
60 SHAM 2.9 ± 0.24*
7 R 19.3 ± 1.6†
60 R 3.1 ± 0.11*
PI was expressed as proliferating cells per 100 hepatocytes. All values are shown as the mean 
± SEM. *p < 0.05 vs corresponding to seven days. †p < 0.05 vs respective Sham.
M.C. Vera et al.




HT performed with hepatocytes obtained from preneoplas-
tic rat livers and the impact of this procedure on healthy 
recipients was analyzed in this study. We proved that all 
recipients from group R developed small and very isolated 
FAH. We also showed that these FAH did not progress to 
PHDT and persisted in the receptor livers during the study 
period. 
The enzymatic and PT activities were normal and there 
were no statistical differences between the number of FAH 
per cm2 of hepatic tissue and the percentage of liver occu-
pied by foci from day seven and 60 after HT. These results 
suggest that liver biochemical feature and liver protein 
biosynthetic capability were intact after two months of HT. 
Furthermore, even though there were a few and scattered 
FAH in recipient livers, they did not increase in numbers 
or size. Moreover, no foci progressed to PHDT; this data 
was obtained when the hepatic morphology was analyzed 
with hematoxylin-eosin and rGST-Pi immunostaining 60 
days after transplantation. The PI indicated that replicating 
cells were scarce at day 60 compared to day 7 after par-
tial hepatectomy when livers were still in the regenerating 
process. This was true for recipients who received 150,000 
hepatocytes or the vehicle alone. HT did not interfere in the 
hepatic regeneration process, as there were no statistically 
significant differences in PI at day 7.
This is the first study to demonstrate a preliminary assess-
ment of the risks of HT in rats when using marginal donors. 
Thus, this study could be useful to estimate how long the 
preneoplastic-transplanted hepatocytes remain in the recip-
ient, in cases where HT is used as a temporal bridge and the 
whole liver is transplanted within few days. Further studies 
on FAH development in rat recipient livers are needed to 
assess if this constitutes a severe risk for the recipients’ 
health. 
There are some limitations associated to this procedure. 
Even though rGST-Pi is a frequently used and reliable mark-
er for FAH in rat livers, it does not mean that persistent FAH 
could change their cellular phenotype during progression, 
as demonstrated in many studies by cytomorphological, 
cytochemical, microbiochemical and molecular methods 
(27). Thus, it is necessary to analyze FAH phenotype evo-
lution over time in our experimental study. Furthermore, 
there is a chance of uneven transplanted cell distribution, 
which may cause overestimation or underestimation of 
engrafted cells with the stereological method used. Finally, 
other tissues must be monitored as transplanted cells have 
the potential to induce the development of HCC. The organs 
that should be studied include the spleen, since many 
injected hepatocytes remain in the splenic parenchyma, and 
also the lungs, as transplanted hepatocytes can migrate to 
these organs via the inferior cava vein (28,29). Lymph nodes 
should also be studied as some preneoplastic cells can be 
trapped in the parenchyma arriving via lymphatic circula-
tion. If the amount of cells transplanted is controlled, the 
formation of micro emboli of hepatocytes could be avoided 
and the HT can be performed directly by injection in the 
portal vein, thus avoiding the permanence of these cells 
in the spleen (29). Functional studies in recipients should 
also be performed together with a complete histological 
analysis of the organs mentioned above.
We conclude that all rat recipients developed FAH and they 
persisted until 60 days post-transplant. FAH number and 
size did not increase during the study period and PI con-
firmed normal hepatic regeneration. Furthermore, the enzy-
matic profile and the percentage of PT activity was normal 
60 days post-HT and finally and most importantly, FAH did 
not progress to PHDT under our experimental conditions. 
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